Compare Cassava Sciences Inc (FLNA) vs Home Depot Inc (HD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Home Depot Inc — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Home Depot Inc trades at $347.47 (market cap $340.46B). The key difference: Home Depot Inc is far larger — about 6406.8× Cassava Sciences Inc's market cap, and Home Depot Inc pays a 2.73% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | HD | |
|---|---|---|
Market Cap | $53.14M | $340.46B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $423.42 |
52-Week Low | $1.09 | $297.51 |
Enterprise Value | -$33.43M | $402.01B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Home Depot (HD) trades at $347.82, up 2.98% with bullish technical signals and strong institutional support. The stock shows robust fundamentals with $159.51B revenue and 8.41% net margin, though recent earnings mixed with Q3 miss but Q4 and Q1 beats. Valuation metrics include P/E of 24.25 and ROE of 128.38%, while cash flow trends indicate strategic investments. Recent news highlights institutional activity and market volatility concerns.
Outlook remains positive with analyst consensus target of $370.59 and 59% buy ratings, supported by Pro business growth and housing tailwinds. Risks include weakening big-ticket demand, margin pressure from investments, and rising mortgage rates impacting housing market sentiment. The stock presents a buying opportunity for long-term investors despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Home Depot Inc
Home Depot is the world's largest home improvement specialty retailer, operating more than 2,300 warehouse-format stores offering more than 30,000 products in store and 1 million products online in the United States, Canada, and Mexico. Its stores offer numerous building materials, home improvement products, lawn and garden products, and decor products and provide various services, including home improvement installation services and tool and equipment rentals. The acquisition of distributor Interline Brands in 2015 allowed Home Depot to enter the maintenance, repair, and operations business, which has been expanded through the tie-up with HD Supply (2020). The addition of the Company Store brought textile exposure to Home Depot's lineup.
Read more on HD →
